澳大利亚生物技术公司免疫基因（Imugene）今日宣布完成两项重要融资安排。根据公告，该公司已获得机构投资者承诺认购价值2250万美元的配售股份，每股定价为0.33澳元。与此同时，公司还启动了股票购买计划，拟以相同每股价格向现有股东募资最高1500万澳元。
此次配售定价较该公司最近收盘价折让约12%，融资总额相当于当前市值的近两成。双轨融资方案将为免疫基因推进肿瘤免疫疗法临床研究提供充足资金支持。市场人士指出，0.33澳元的统一定价策略既保障了机构投资者的参与意愿，也为后续股东认购提供了明确价格指引。
免疫基因专注于开发新型癌症免疫疗法，其主打产品PD1-Vaxx已进入转移性结直肠癌II期临床试验阶段。此次融资将加速该公司多款候选药物的临床开发进程，包括正在评估中的B细胞靶向疗法和溶瘤病毒平台。澳交所数据显示，该公司股价过去三个月累计上涨逾40%，反映出市场对其技术平台前景的积极预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.